News

Sanofi, a global healthcare leader, and the Institut Pasteur, an internationally renowned center for biomedical research, recently honored four researchers with the Sanofi – Institut Pasteur Awards 2015 for their work in the fields of immunology and tropical and neglected diseases. One of the awardees, laureate in the Senior…

In a new study entitled “Reduced cortical microvascular oxygenation in multiple sclerosis: a blinded, case-controlled study using a novel quantitative near-infrared spectroscopy method,” a team of researchers at the Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary investigated whether frequency domain near-infrared spectroscopy technology can measure the potential…

Mitsubishi Motors North America, Inc. (MMNA) recently announced a nationwide auction of its first Mitsubishi Lancer Evolution Final Edition to raise money for the National Multiple Sclerosis Society. The auction is currently ongoing on eBay  and bidding will conclude on Nov. 21 at the 29th annual MS Dinner Auction, sponsored…

In a recent study entitled “Promotion of Remyelination by Sulfasalazine in a Transgenic Zebrafish Model of Demyelination,” researchers investigated whether sulfasalazine treatment, an anti-inflammatory and immune-modulating drug, could promote remyelination of axons in an organism model of demyelination diseases such as multiple sclerosis (MS). The study was published in the…

A new partnership between ARM and HeartToHeart Networks LLC has brought healthcare providers of patients with neurodegenerative disorders, such as multiple sclerosis, a new and secure tool for remote health management. The novel health management (RHM) solution combines technology from both companies. It uses mobile devices adapted with a Trusted…

A major new report published by the U.K. MS Trust has determined that the country’s National Health Services (NHS) programs relied on by people living with multiple sclerosis (MS) are facing increasing pressures that could lead to inequities in care. Evidence from the Letchworth Garden City, Hertfordshire based MS Trust’s…

In a new study entitled “Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis,” a team of researchers performed a comparative analysis of metabolites between control mice and a mouse model with experimental autoimmune encephalitis (EAE, the most commonly used…

Roche recently provided an update on their late-stage pipeline products across several therapeutic areas, including ocrelizumab for the treatment of multiple sclerosis. The data was disclosed on Nov. 5 at the Roche Pharma Day 2015 event in London, U.K. Ocrelizumab was previously revealed to be the first investigational medicine…

MyTomorrows, a company that provides information and facilitates requests regarding clinical trials, diagnostic tests and medicines through its internet-based platform, and Hemispherx Biopharma, Inc, a pharmaceutical company specialized in the development of new therapies for life-threatening disorders, have partnered in an effort to make Hemispherx’s natural alpha interferon therapy…

In a recent study entitled “Myeloid cells as target of fingolimod action in multiple sclerosis,” a team of scientists investigated the impact of fingolimod (Gilenya, Novartis), an approved drug for multiple sclerosis (MS), on the reactivity of myeloid cells, a key group that comprises several immune cells that…

Two upcoming, free events for members of the multiple sclerosis community are to be held during the next few weeks at Coral Gables, Florida, and San Antonio, Texas, respectively. Sponsored by the pharmaceutical firm Genzyme, these interactive events will provide opportunities for people with MS and members of the MS community…

The National Multiple Sclerosis Society has dedicated over $21 million to fund 78 new multiple sclerosis (MS) research studies as part of a broad research plan designed to address MS, re-establish  lost functioning caused by the disease in patients, and ultimately end the disease forever. This recent round of investment into MS research is…

Fitbit, a company dedicated to the development of health and fitness products and experiences to help individuals adopt healthier lifestyles, recently announced the FitForGood initiative, a step challenge encouraging Fitbit fans to get fit for a good cause — with their steps translating into funding for three national non-profit organizations:…

A smartphone platform may eventually enable large-scale studies of patients with multiple sclerosis (MS) or other neurologic diseases, according to the findings of a recent study published in the journal Neurology, Neuroimmunology & Neuroinflammation. Smartphones, highly portable and popular, provide a significant opportunity to incorporate information across…

In a recent study entitled “MicroRNA expression profiling of human blood monocyte subsets highlights functional differences,” a team of researchers discovered a pool of 66 microRNAs that underlie differences in phenotype and function of a group of immune cells with key roles in multiple sclerosis. The study was published…

Findings from a recent study published in the Journal of Neurologic Physical Therapy showed that standard approaches to evaluating muscular strength and cardiorespiratory fitness among patients with multiple sclerosis (MS) might be underestimating the patients’ capacities, encouraging clinicians to prescribe less effective exercises. In the study entitled “…

In a recent study published in the journal Immunity, researchers at the Weizmann Institute of Science in Israel reported the findings that a small subtype of immune dendritic cells plays a role in the prevention of both metabolic syndrome and autoimmunity. The study is entitled “…

In a new study entitled “Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation,” a team of scientists discovered the mechanism by which autoreactive T cells are capable of penetrating a patient’s brain and induce multiple sclerosis. The study was recently published in the advance online issue…

Alkermes plc, a fully integrated global biopharmaceutical company, recently provided a regulatory update and positive clinical trial data for ALKS 8700, an oral, innovative and proprietary monomethyl fumarate (MMF) compound that is being developed to treat multiple sclerosis (MS). ALKS 8700 is being developed to quickly and efficiently convert…

Psychiatric comorbidity is common in patients with multiple sclerosis (MS), and affects the MS community more frequently than a matched control population, although the incidence is stable over time, according to recent findings of a study published in the journal Neurology, the Official Journal of the American Academy…

Helius Medical Technologies, Inc., a company dedicated to neurological wellness, recently announced that the multiple sclerosis (MS) pilot study assessing the company’s investigational Portable Neuromodulation Stimulator (PoNS™) device has met all of the study’s goals. PoNS is a non-invasive device that allows the delivery of neurostimulation through the…

A collective team of physician-researchers comprising Dr. Peter Calabresi from Johns Hopkins School of Medicine in Baltimore, Dr. Laura Balcer from NYU Langone Medical Center, and Dr. Elliot Frohman from University of Texas Southwestern School of Medicine are the winners of the 2015 Barancik Prize for Innovation…

PathMaker Neurosystems Inc., a clinical-stage neuromodulation company focused on non-invasive therapies for neuromotor disorders, recently announced that the U.S. Food and Drug Administration (FDA) has granted the company’s MyoRegulator™ PM-2200 system the Expedited Access Pathway (EAP) designation and priority processing status. The MyoRegulator is the first product of PathMaker…

New research at the University of Adelaide, Australia, may help pave the way toward the potential inhibition of multiple sclerosis (MS) and other autoimmune diseases. The study entitled “CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells” was published in the journal …

Overcoming Multiple Sclerosis (OMS), a non-profit organization that promotes a program based on a scientifically tested diet and lifestyle management with the goal of improving the health status and quality of life of individuals with multiple sclerosis (MS), recently announced that it will expand into the United States. OMS…

Results from a recent study published in the journal Rehabilitation Research and Practice showed the positive effects of community exercise programs in multiple sclerosis (MS) patients. Study participants showed physical improvements like higher energy levels and reduced fatigue, psychological benefits from those improvements and from group support and motivation, and…

In a new article published in the journal Trends in Biotechnology, Korean researchers suggest that diseases of the central nervous system (CNS) might be better studied using compact, accessible chip technology than in current methods. The report, titled “Central Nervous System and its Disease…

In a recent study published in the journal BMJ Open, a research team explored the use of fatigue management strategies in patients with multiple sclerosis (MS) who attended a group-based fatigue management program. The Multiple Sclerosis Council for Clinical Practice Guidelines defines fatigue as “a subjective lack…

RnR Market Research, a company offering market research reports on fields that include healthcare, pharmaceutical, technology, energy, and industry, recently publicized a new report on the epidemiology of multiple sclerosis (MS) and a forecast of its therapeutic market value. The report is entitled “EpiCast Report: Multiple Sclerosis – Epidemiology…

The Consortium of Multiple Sclerosis Centers (CMSC), an organization for researchers and healthcare professionals committed to multiple sclerosis (MS) care and treatment, has recently issued a position statement claiming that prescribers should have the right to make clinical decisions on the best treatments and medications in each individual MS case.